Search

Displaying results 6191 - 6200 of 7181 in total
  1. Drug

    Galegenimab

    go.drugbank.com/drugs/DB18860
    Investigational

    Galegenimab is under investigation in clinical trial NCT03972709 (A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to

  2. Drug

    Chlorfenson

    go.drugbank.com/drugs/DB05377
    Experimental

    Chlorfenson is developed by Moberg Derma for the treatment of onychomycosis (nail fungus) as the primary indication.

  3. Drug

    OPC-28326

    go.drugbank.com/drugs/DB05461
    Experimental

    At low doses, OPC 28326 selectively vasodilates the femoral arterial bed due to its inhibitory action at alpha-2-adrenoceptors while having minimal action on systemic blood pressure, heart rate and coronary

  4. Drug

    IMCY-0141

    go.drugbank.com/drugs/DB17019
    Investigational

    IMCY-0141 is a synthetic peptide based on MOG (Myelin Oligodendrocyte Glycoprotein), a dominant autoantigen, designed to stop the progression of multiple sclerosis (MS) and the destruction of the myelin

  5. Drug

    Fianlimab

    go.drugbank.com/drugs/DB18858
    Investigational

    Fianlimab is under investigation in clinical trial NCT06190951 (A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-pd1 Alone in Adult Participants With Resectable Stage 3 or

  6. Drug

    LI-301

    go.drugbank.com/drugs/DB05509
    Experimental

    LI 301 is an orally bio-available compound delivered in a fast melt mechanism with taste masking enabling it to be taken anytime without water. … This results in a slight dulling of sensation that can be used to treat premature ejaculation without interfering with normal sexual pleasure or orgasm.

  7. Drug

    Ketazolam

    go.drugbank.com/drugs/DB01587
    ApprovedWithdrawn

    Ketazolam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant activity. Ketazolam is not approved in Canada or America.

  8. Drug

    CVT-6883

    go.drugbank.com/drugs/DB05936
    Experimental

    CVT-6883 is a selective, potent and orally available A2B-adenosine receptor antagonist which CV Therapeutics is investigating for the potential treatment of asthma and other conditions related to inflammation

  9. Drug

    Molibresib

    go.drugbank.com/drugs/DB16239
    Investigational

    Molibresib is under investigation in clinical trial NCT01943851 (A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects

  10. Drug

    Ociperlimab

    go.drugbank.com/drugs/DB18947
    Investigational

    Ociperlimab is under investigation in clinical trial NCT04866017 (A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (Ccrt) in Patients With Stage

    Synonyms: Immunoglobulin g1-kappa, anti-(homo sapiens tigit (t-cell immunoreceptor with ig domain and itim, v-set ig member 9, vsig9, v-set and transmembrane member 3, vstm3)), humanized monoclonal antibody (ociperlimab